"label","id","rationale","uuid:ID","name","description","instanceType"
"","StudyDesign_1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","fd69b290-bd10-4ed6-ba60-0ab85a84e976","Study Design 1","The main design for the study","StudyDesign"
